

**COMBINED DECLARATION AND POWER OF ATTORNEY**

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated next to my name.

I believe I am original, first and joint inventor of the subject matter that is claimed and for which a patent is sought on the invention entitled:

COMBINATION COMPRISING N-(3-METHOXY-5-METHYLPYRAZIN-2-YL)-2-(4-[1,3,4-OXADIAZOL-2-YL]PHENYL)PYRIDINE-3-SULPHONAMIDE AND AN LHRH ANALOGUE AND/OR BISPHOSPHONATE

the specification of which:

- ☐ is attached hereto.
- OR ☐ was filed on \_\_\_\_\_ with Express Mail No. \_\_\_\_\_ (Application Number not yet known).
- OR ☒ was filed on September 2, 2004 as United States Application Number 10/569,583 (371 filing date February 23, 2006) or PCT International Application Number PCT/GB2004/003733, filed on September 2, 2004 and was amended on February 23, 2006, September 12, 2007 and January 17, 2008.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the office all information known to me to be material to patentability as defined in 37 CFR §1.56.

I hereby claim the benefit under Title 35, United States Code, §119(e)(1) of any United States provisional application(s) listed below:

U.S. Serial No.	Filing Date	Status

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s), or §365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information known to be material to patentability as defined in 37 CFR §1.56 of which I became aware between the filing date of the prior application and the national or PCT international filing date of this application:

U.S. Serial No.	Filing Date	Status

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application designating at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Application No.	Filing Date	Priority Claimed	
GB	0320806.3	September 5, 2003	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
			<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby appoint all registered practitioners associated with **Customer Number 44992** to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to:

**Customer Number 44992**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: CURWEN, Jon Owen


Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence Address: Macclesfield, UK

Citizenship: British

Post Office Address: AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire, SK10 4TG, United Kingdom

Full Name of Inventor: GALLAGHER, Neil

Inventor's Signature:  Date: 25/8/2008

Residence Address: Cambridge, UK

Citizenship: IE

Post Office Address: Novartis Pharma AG, WSJ-103.3.09.19, Postfach 4002, Basel, Switzerland formerly of AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire, SK10 4TG, United Kingdom

**COMBINED DECLARATION AND POWER OF ATTORNEY**

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated next to my name.

I believe I an original, first and joint inventor of the subject matter that is claimed and for which a patent is sought on the invention entitled:

COMBINATION COMPRISING N-(3-METHOXY-5-METHYLPYRAZIN-2-YL)-2-(4-[1,3,4-OXADIAZOL-2-YL]PHENYL)PYRIDINE-3-SULPHONAMIDE AND AN LHRH ANALOGUE AND/OR BISPHOSPHONATE

the specification of which:

☐ is attached hereto.

OR

☐ was filed on \_\_\_\_\_ with Express Mail No. \_\_\_\_\_ (Application Number not yet known).

OR

☒ was filed on September 2, 2004 as United States Application Number 10/569,583 (371 filing date February 23, 2006) or PCT International Application Number PCT/GB2004/003733, filed on September 2, 2004 and was amended on February 23, 2006, September 12, 2007 and January 17, 2008.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the office all information known to me to be material to patentability as defined in 37 CFR §1.56.

I hereby claim the benefit under Title 35, United States Code, §119(e)(1) of any United States provisional application(s) listed below:

U.S. Serial No.	Filing Date	Status

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s), or §365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information known to be material to patentability as defined in 37 CFR §1.56 of which I became aware between the filing date of the prior application and the national or PCT international filing date of this application:

U.S. Serial No.	Filing Date	Status

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application designating at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:


Country	Application No.	Filing Date	Priority Claimed	
GB	0320806.3	September 5, 2003	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
			<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby appoint all registered practitioners associated with Customer Number 44992 to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to:

Customer Number 44992

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: CURWEN, Jon Owen

Inventor's Signature: 

Date: 19<sup>th</sup> August 2008.

Residence Address: Macclesfield, UK

Citizenship: British

Post Office Address: AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire, SK10 4TG, United Kingdom

Full Name of Inventor: GALLAGHER, Neil

Inventor's Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Residence Address: Cambridge, UK

Citizenship: IE

Post Office Address: Novartis Pharma AG, WSJ-103.3.09.19, Postfach 4002, Basel, Switzerland formerly of AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire, SK10 4TG, United Kingdom